[주총 포커스] 강스템바이오텍, 소통 부재ㆍ스톡옵션 논란에 '진땀'

Kangstembiotech's shareholder meeting exposed a critical communication breakdown between management and minority shareholders. Despite three capital increases generating 966 billion won with minimal disclosure, the company's plan to grant stock options amid a 73% shareholder value loss sparked fierce backlash. This case exemplifies the tension biotech startups face between fundraising and employee incentives, highlighting the urgent need for structured shareholder engagement practices.